Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 9/20 | 0.41 |
| ▸ | CTSK | P43235 | 8/20 | 0.41 |
| ▸ | CTSS | P25774 | 8/20 | 0.41 |
| ▸ | CTSB | P07858 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4652077 | 0.82 | CTSK (0.48) | CTSCKCNH2CTSLCTSKCTSS | |
| SCHEMBL6252182 | 0.82 | CTSK (0.48) | CTSCKCNH2CTSLCTSKCTSS | |
| SCHEMBL18664188 | 0.82 | HTT (0.44) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL6183365 | 0.77 | CTSK (0.44) | CTSCKCNH2CTSLCTSKCTSS | |
| SCHEMBL5330574 | 0.76 | CYP2D6 (0.39) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL1515589 | 0.74 | CTSC (0.37) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL24503023 | 0.73 | CTSC (0.50) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL18664190 | 0.71 | HTT (0.38) | CTSCKCNH2LTB4RLTB4R2 | |
| SCHEMBL12955348 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL15795178 | 0.67 | KMT2A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-11-14 | — | — | US | disclosed |
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-09-07 | — | — | US | disclosed |
| EP-3323814-B1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2020-05-13 | — | — | EP | disclosed |
| EP-3323814-A1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CTSC 7/4885KCNH2 2475/4885LTB4R 636/4885 |
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CTSC 7/4885KCNH2 2278/4885LTB4R 635/4885 |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | CTSC 7/4885KCNH2 2475/4885LTB4R 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.